Vanguard Portfolio Management
ATYR

Vanguard Portfolio Management’s aTyr Pharma ATYR Stock Holding History

Vanguard Portfolio Management’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-569,227
Closed -$444K – 3267
2026
Q1 		$444K Buy
+569,227
New +$481K ﹤0.01% 2963

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Portfolio Management's ATYR Position: Q2 2026 in Review

Vanguard Portfolio Management sold out of aTyr Pharma (ATYR) in Q2 2026, closing a stake of 569,227 shares — an estimated $444K sold.

Vanguard Portfolio Management first reported a position in ATYR in Q1 2026 and held it in 1 quarter. The position peaked at $444K in Q1 2026. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Vanguard Portfolio Management reported no remaining aTyr Pharma position as of Q2 2026 after selling out during the quarter.
  • Vanguard Portfolio Management sold 569,227 aTyr Pharma shares in Q2 2026, an estimated $444K.
  • Vanguard Portfolio Management first reported a position in aTyr Pharma in Q1 2026 and held it in 1 quarter.
  • Vanguard Portfolio Management's aTyr Pharma position peaked at $444K in Q1 2026.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.